Zoek een klinische studie of trial
Andere zoekoptie(s)
26 Resultaat/Resultaten
Aanwerving proef
= 
; Lopend onderzoek
= 
; Gefinancierd door een IRDiRC-lid = 
Nationale klinische studie(s)
CANADA
Ontario
TORONTO
Assessing the Safety, Feasibility, Cost Effectiveness and Patient Satisfaction of Outpatient Administration of High Dose Methotrexate (HD MTX) in Patients With Osteosarcoma (Phase III) (Completed)
The Hospital for Sick Children
DUITSLAND
Baden-Württemberg
HEIDELBERG
Phase I/II therapy trial to determine the safety and efficacy of heavy Ion Radiotherapy in patients with Osteosarcoma - DE
Neurologische Universitätsklinik Heidelberg
Klinik für Radioonkologie und Strahlentherapie
DUITSLAND
Baden-Württemberg
STUTTGART
EURAMOS I: A randomized trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable Osteosarcoma based on histological response to pre-operative chemotherapy (Phase III)
Klinikum Stuttgart - Standort Olgahospital
COSS (Cooperative OsteoSarkom Studiengruppe) Studienzentrale
DUITSLAND
Baden-Württemberg
STUTTGART
EURO-B.O.S.S.: A European treatment protocol for bone sarcoma in patients older than 40 years - DE
Klinikum Stuttgart - Standort Olgahospital
COSS (Cooperative OsteoSarkom Studiengruppe) Studienzentrale
FRANKRIJK
AUVERGNE-RHONE-ALPES
ADDRESS: NOT PROVIDED - FR
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas - FR
Institution: Information not provided - FR
FRANKRIJK
AUVERGNE-RHONE-ALPES
LYON
Efficacy and Tolerance Adjuvant High-Dose Thiotepa With Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma (Phase II)
CHU de Lyon HCL - GH Est-Institut d'hématologie et d'oncologie pédiatrique IHOP
Soins palliatifs pédiatriques
FRANKRIJK
ILE-DE-FRANCE
VILLEJUIF
Open Label, Pilot Phase II Study of Glivec in Children and Adolescents with Life Threatening Diseases Known to be associated with one or more Glivec-Sensitive Tyrosine Kinases - FR
CLCC Institut Gustave Roussy
Département de cancérologie de l'enfant et de l'adolescent
FRANKRIJK
ILE-DE-FRANCE
VILLEJUIF
Phase 2 single-arm study of gemcitabine in combination with oxaliplatin in refractory and relapsed pediatric solid tumors - Terminated -
CLCC Institut Gustave Roussy
Département de cancérologie de l'enfant et de l'adolescent
ITALIË
PIEMONTE
CANDIOLO
A phase II, open label, non-randomized study of second or third line treatment with the combination of sorafenib and everolimus in patients affected by relapsed and non-resectable high-grade osteosarcoma - SERIO
Istituto per la Ricerca e la Cura del Cancro
Oncologia Medica e Centro Trapianti
OOSTENRIJK
WIEN
WIEN
An early-phase, multicenter, open-label study of the safety and pharmacokinetics of anti-PD-L1 antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors (phase I-II) - AT
St. Anna Kinderspital
Zentrum für Kinder- und Jugendheilkunde
SPANJE
Andalucía
SEVILLA
GEIS-51: Phase II multicenter trial of palbociclib in second line of advanced sarcomas with CDK4 overexpression - ES
Hospital Universitario Virgen del Rocío
MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA)
SPANJE
Andalucía
SEVILLA
GEIS-52: Phase I-II trial of sunitinib plus nivolumab after standard treatment in advanced soft tissue and bone sarcomas - ES
Hospital Universitario Virgen del Rocío
MUsculoSkeletal Tumor Board of Excellence Sevilla (MUSTBE SEVILLA)
SPANJE
Cataluña
ESPLUGUES DE LLOBREGAT
Phase II multicentric and prospective trial with gemcitabine and rapamycin in second line of metastatic osteosarcoma - ES (completed)
Hospital Sant Joan de Déu Barcelona
Servicio de Oncología y Hematología
SPANJE
Cataluña
ESPLUGUES DE LLOBREGAT
An early-phase, multicenter, open-label study of the safety and pharmacokinetics of Anti-PD-L1 Antibody (MPDL3280A) in pediatric and young adult patients with previously treated solid tumors (Phase I-II)- ES
Hospital Sant Joan de Déu Barcelona
Servicio de Oncología y Hematología
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas - ES (completed)
Institution: Information not provided - ES
SPANJE
Madrid
ADDRESS: NOT PROVIDED - ES
A Study to Determine the Activity of SCH 717454 in Subjects With Osteosarcoma or Ewing's Sarcoma That Has Relapsed After Standard Systemic Therapy (Phase II) (terminated)
Institution: Information not provided - ES
SPANJE
Madrid
MADRID
Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies - ES
Hospital Infantil Universitario Niño Jesús
Servicio de Oncohematología
VERENIGD KONINKRIJK
Greater London
LONDON
EURAMOS I: A Randomized Trial of the European and American Osteosarcoma Study Group to Optimize Treatment Strategies for Resectable Osteosarcoma Based on Histological Response to Pre-Operative Chemotherapy (Phase III Intergroup Study) - UK (Completed)
University College Hospital
Joint Lymphoma Clinic, 1st Floor Central
VERENIGD KONINKRIJK
Greater Manchester
ADDRESS: NOT PROVIDED - UK
NO21157: A Phase II Trial of R1507, a Recombinant Human Monoclonal Antibody to the Insulin-Like Growth Factor-1 Receptor for the Treatment of Patients With Recurrent or Refractory Ewing's Sarcoma, Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and Other Sarcomas - UK
Institution: Information not provided - UK
VERENIGD KONINKRIJK
West Yorkshire
LEEDS
BO06: A Randomised Trial of pre-operative and post-operative doxorubicin plus cisplatin at standard dose or increased dose intensity with Granulocyte Colony-Stimulating Factor (G-CSF) in Operable Osteosarcoma (Phase III) - UK (Completed))
St James's University Hospital
Childrens Adolescent Oncology and Haematology
DUITSLAND
Nordrhein-Westfalen
BIELEFELD
A Phase II Trial of R1507, a recombinant human monoclonal antibody to the insulin-like growth factor-1 receptor for the treatment of patients with recurrent or refractory Ewing's Sarcoma, recurrent or refractory Osteosarcoma, Synovial Sarcoma, Rhabdomyosarcoma and other Sarcomas - DE
Franziskus Hospital Bielefeld
Klinik für Hämatologie, Onkologie und Immunologie
NEDERLAND
Zuid-Holland
LEIDEN
Adjuvans Zoledronaat in 'High Risk' Giant Cell bot tumoren (GCT) - een gerandomiseerde fase II Studie
LUMC - Leids Universitair Medisch Centrum
Afdeling Klinische Oncologie
CANADA
Ontario
HAMILTON
FGFR Study: Proof-of-concept study of AZD 4547 in patients with FGFR1 or FGFR2 amplified tumours - UK
McMaster University
Department of Medicine
VERENIGD KONINKRIJK
Greater Manchester
ADDRESS: NOT PROVIDED - UK
An Open-Label Phase I/IIa Study of Intravenous BAL101553 in Adult Patients with Advanced Solid Tumors
Institution: Information not provided - UK
Multinationale klinische studie(s)
FRANKRIJK
AUVERGNE-RHONE-ALPES
LYON
EUROSARC: European Clinical trials in Rare Sarcomas within an integrated translational trial network
CLCC Léon Bérard
Centre Léon Bérard
ZWITSERLAND
Suisse Alémanique
BASEL